Effects of preventive group education on the resistance of LDL against oxidation and risk factors for coronary heart disease in bypass surgery patients

Annals of Medicine

Volumn 34, Issue 4, 2002, Pages 272-283

  Palomäki, Ari ^a   Miilunpalo, Seppo ^a   Holm, Päivi ^a   Mäkinen, Enja ^a   Malminiemi, Kimmo ^a  

^a KANTA HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

CABG; Cardiovascular surgery; Coronary disease; Health education; LDL oxidation; Lipoproteins; Physical activity; Secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; FIBRINOGEN; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER;

ADULT; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; EDUCATION PROGRAM; FEMALE; FINLAND; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NUTRITION; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SECONDARY PREVENTION;

ANTIOXIDANTS; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENERGY INTAKE; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; NUTRITION PHYSIOLOGY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); OXIDATION-REDUCTION; PATIENT EDUCATION; PREVENTIVE HEALTH SERVICES; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS;

EID: 0036377983     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902320322538     Document Type: Article

References (55)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-25.
2. Regnström J, Nilsson J, Törnvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992; 339: 1183-6.
3. Chiu H-C, Jeng J-R, Shieh S-M. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. Biochim Biophys Acta 1994; 1225: 200-8.
4. Chirico S, Smith C, Marchant C, Mitchinson MJ, Halliwell B. Lipid peroxidation in hyperlipidaemic patients. A study of plasma using an HPLC-based thiobarbituric acid test. Free Radic Res 1993; 19: 51-7.
5. Kovacs IB, Jahangiri M, Rees GM, Gorog P. Elevated plasma lipid hydroperoxides in patients with coronary artery disease. Am Heart J 1997; 134: 572-6.
6. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb Vasc Biol 1994; 14: 32-40.
7. Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991; 337: 1-5.
8. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53: 326S-34S.
9. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342: 1007-11.
10. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
11. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
12. Stephens NG, Parsons A, Schonfield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
13. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55.
14. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Trialists Collaboration. Lancet 1994; 344: 563-70.
15. Naunheim KS, Fiore AC, Wadley JJ, McBride LR, Kanter KR, Pennington DG, et al. The changing profile of the patient undergoing coronary artery bypass surgery. J Am Coll Cardiol 1988; 11: 494-8.
16. Updated in 1995: Fiore AC, Naunheim KS. The changing mortality of myocardial revascularization: coronary artery bypass and angioplasty. Ann Thorac Surg 1995; 60: 738-9.
17. Grondin CM and Thornton JC. The natural history of saphenous vein grafts. In: Lüscher TF, Turina M and Braunwald E, eds: Coronary artery graft disease Mechanisms and prevention. Heidelberg: Springer-Verlag 1994: 3-15.
18. Bathgate AJ, Irving JB. Ten year follow up of patients referred for coronary artery bypass grafting from a single district general hospital. Heart 1997; 78: 584-6.
19. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986; 6: 594-600.
20. Lindén T, Bondjers G, Karlsson T, Wiklund O. Serum triglycerides and HDL cholesterol - major predictors of long-term survival after coronary surgery. Eur Heart J 1994; 15: 747-52.
21. Daida H, Yokoi H, Miyano H, Mokuno H, Satoh H, Kottke TE, et al. Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol 1995; 25: 193-7.
22. Engblom E, Rönnemaa T, Hämäläinen H, Kallio V, Vänttinen E, Knuts L-R. Coronary heart disease risk factors before and after bypass surgery: results of a controlled trial on multifactorial rehabilitation. Eur Heart J 1992; 13: 232-7.
23. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
24. Haapanen N, Miilunpalo S, Vuori I, Oja P, Pasanen M. Characteristics of leisure time physical activity associated with decreased risk of premature all-cause and cardiovascular disease mortality in middle-aged men. Am J Epidemiol 1996; 143: 870-80.
25. Hakala P, Marniemi J, Knuts L-R, Kumpulainen J, Tahvonen R, Plaami S. Calculated versus analysed nutrient composition of weight reduction diets. Food Chem Toxicol 1996; 57: 71-5.
26. Simell O, Niinikoski H, Viikari J, Rask-Nissilä L, Tammi A, Rönnemaa T. Cardiovascular disease risk factors in young children in the STRIP baby project. Ann Med 1999; 31(Suppl 1): 55-61.
27. Metsä-Ketelä T. Luminescent assay for total peroxyl radical trapping capacity of plasma. In: Stanley PE and Kricka LJ, eds. Bioluminescence and chemiluminescence: current status. Chichester: John Wiley & Sons; 1991: 389-92.
28. Malminiemi K, Palomäki A, Malminiemi O. Comparison of LDL trap assay to other tests of antioxidant capacity; effect of vitamin E and lovastatin treatment. Free Radic Res 2000; 33: 581-93.
29. Niki E, Yamamoto Y, Komuro E, Sato K. Membrane damage due to lipid oxidation. Am J Clin Nutr 1991; 53: 201S-5S.
30. Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and α-tocopherol during lovastatin treatment. FEBS Lett 1997; 410: 254-8.
31. Kleemola P, Virtanen M, Pietinen P. The 1992 Dietary survey of Finnish adults. National Public Health Institute, Helsinki 1994; 13-9, 24.
32. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-33.
33. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, et al. Regular physical exercise and low-fat diet, effects on progression of coronary artery disease. Circulation 1992; 86: 1-11.
34. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9.
35. Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R, Ghosh S, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992; 304: 1015-9.
36. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-9.
37. Ginsburg GS, Agil A, O'Toole M, Rimm E, Douglas PS, Rifai N. Effects of a single bout of ultraendurance exercise on lipid levels and susceptibility of lipids to peroxidation in triathletes. JAMA 1996; 276: 221-5.
38. Vasankari TJ, Kujala UM, Vuorimaa T, Ahotupa M. Effects of acute prolonged exercise on serum and LDL oxidation and antioxidant defences. Free Radic Biol Med 1997; 22: 509-13.
39. Vasankari T, Lehtonen-Veromaa M, Möttönen T, Ahotupa M, Irjala K, Heinonen O, et al. Reduced mildly oxidized LDL in young female athletes. Atherosclerosis. 2000; 151: 399-405.
40. Salonen R, Nyyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76: 34C-9C.
41. Halle M, Berg A, Baumstark MW, Keul J. Association of physical fitness with LDL and HDL subfractions in young healthy men. Int J Sports Med 1999; 20: 464-9.
42. de Rijke YB, Bredie SJ, Demacker PN, Vogelaar JM, Hak-Lemmers HL, Stalenhoef AF. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17: 127-33.
43. Mänttäri M, Javela K, Koskinen P, Pikkarainen J, Manninen V, Huttunen JK, et al. Seasonal variation in high density lipoprotein cholesterol. Atherosclerosis 1993; 100: 257-65.
44. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102: 2329-34
45. Saadeddin S, Habbab M, Ferns G. Markers of inflammation and coronary artery disease. Med Sci Monit 2002; 8: RA5-12.
46. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.
47. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
48. Mehta JL, Li DY. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain? Cardiovasc Res 1999; 43: 291-9.
49. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-62.
50. Northridge DB, Shandall A, Rees A, Buchalter MB. Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit. Br Heart J 1994; 72: 466-7.
51. Euroaspire Study Group. Euroaspire. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-82.
52. Delacrétaz E, Michalopoulos PG, Ruiz J, Saner H, Meier B. Management of hyperlipidaemia after coronary revascularisation: follow up study. BMJ 1998; 316: 1499.
53. Korpilahti K, Engblom E, Syvänne M, Hämäläinen H, Puukka P, Vänttinen E, et al. Angiographic changes in saphenous vein grafts and atherosclerosis risk factors. Stand Cardiovasc J 1998; 32: 343-51.
54. Hunninghake DB, Stein EA, Dujovne CA, Harris WS, Feldman EB, Miller VT, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993; 328: 1213-9.
55. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Nonlipid-related effects of statins. Ann Med 2000; 32: 164-76.